ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

JCR Pharmaceuticals Co., Ltd.

Business Summary

JCR Pharmaceuticals Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following segments: Pharmaceutical Business; and Medical and Research Equipment Business. The Pharmaceutical Business segment deals with the manufacture, purchase, and sale of ethical drugs, active pharmaceutical ingredients, and raw materials. The Medical and Research Equipment Business segment sells medical devices and laboratory equipment. The company was founded by Shin Ashida on September 13, 1975 and is headquartered in Ashiya, Japan.

Financial Highlights

Mar 2021 JPYUSD
Revenue30,085M283.66M
Gross Profit22,273M210.00M
Operating income8,270M77.97M
Income before tax8,653M81.58M
Net income6,892M64.98M
EBITDA10,162M95.81M
Diluted EPS55.520.52
Dividends Per Share120.11
Total Assets74,162M671.14M
Total liabilities35,604M322.20M
Total equity38,383M347.35M
Operating cash flow10,341M97.50M
Currency in JPYCurrency in USD

Historical Data

 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 18,085.03M 20,594M 23,160M 24,781M 30,085M
Gross Profit 12,353.31M 14,466M 16,593M 16,880M 22,273M
Operating income 2,362.00M 3,785M 4,968M 3,245M 8,270M
Income before tax 2,492.78M 3,895M 4,928M 3,422M 8,653M
Net income 1,863.17M 3,069M 3,714M 2,678M 6,892M
EBITDA 3,809.54M 5,167M 6,311M 4,679M 10,162M
Diluted EPS 14.65 24.52 29.98 21.58 55.52
Dividends Per Share 5.50 6.50 7.50 8 12
Total Assets 36,385.03M 38,737M 42,956M 48,118M 74,162M
Total liabilities 8,799.17M 11,206M 12,079M 15,537M 35,604M
Total equity 27,585.00M 27,343M 30,685M 32,390M 38,383M
Operating cash flow 2,651.34M 3,133M 3,905M 4,927M 10,341M
 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 167.00M 185.81M 208.84M 227.92M 283.66M
Gross Profit 114.07M 130.52M 149.62M 155.25M 210.00M
Operating income 21.81M 34.15M 44.79M 29.84M 77.97M
Income before tax 23.02M 35.14M 44.43M 31.47M 81.58M
Net income 17.20M 27.69M 33.49M 24.63M 64.98M
EBITDA 35.17M 46.61M 56.90M 43.03M 95.81M
Diluted EPS 0.13 0.22 0.27 0.19 0.52
Dividends Per Share 0.05 0.05 0.06 0.07 0.11
Total Assets 326.52M 364.24M 388.09M 445.72M 671.14M
Total liabilities 78.96M 105.36M 109.12M 143.92M 322.20M
Total equity 247.55M 257.10M 277.22M 300.03M 347.35M
Operating cash flow 24.48M 28.26M 35.21M 45.31M 97.50M

Valuation Measures

Mar 2021
PER64.24
ROA11.27%
ROE19.47%
Operating margin27.48%
Profit margin22.90%

Key executives

  • Chairman & President: Shin Ashida
  • MD, GM-Research & Head-Corporate Strategy: Hiroyuki Sonoda
  • Executive Officer & General Manager-Administration: Yutaka Honda
  • Executive Officer & General Manager-Research: Toru Hirado
  • Executive Officer & Manager-Overseas Business: Takayo Egawa

Shareholders

  • Medipal Holdings Corp. (22.4%)
  • Kissei Pharmaceutical Co., Ltd. (9.5%)
  • ASHIDA FAMILY (7.6%)
  • JCR Pharmaceuticals Co., Ltd. (4.3%)
  • ASHIDA SHIN (3.6%)
  • Sumitomo Dainippon Pharma Co., Ltd. (2.6%)
  • Nomura Asset Management Co., Ltd. (1.9%)
  • Mochida Pharmaceutical Co., Ltd. (1.6%)
  • The Vanguard Group, Inc. (1.0%)
  • JCR Pharmaceuticals Employee Stock Ownership Plan (0.8%)

Contact Details

Related Companies

  • JCR International SA
  • Jcr Pharmaceuticals Employee Incentive Plan
  • JCR Pharmaceuticals Employee Stock Ownership Plan
  • Dainippon Sumitomo Pharma Co. Ltd. /HGH Business/
  • ArmaGen, Inc.

Competitors

  • BioMarin Pharmaceutical Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Lysogene SA
  • Ascendis Pharma A/S Sponsored ADR
  • Orchard Therapeutics Plc Sponsored ADR
  • SCM LIFESCIENCE CO., LTD
  • Sigilon Therapeutics, Inc.
  • Inventiva SA
  • Sangamo Therapeutics, Inc.
  • Denali Therapeutics Inc.
  • Green Cross Corporation
  • Green Cross Holdings Corporation
  • CORESTEM INC.
Last Updated on 26 Nov, 2021

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more